Building upon over a decade of experience as the leading gene synthesis supplier in the US, GenScript has developed a new breakthrough technology: GenPlus Next-Generation Gene Synthesis. GenPlus
Approximately 146 patients have been enrolled in the Phase III study to date. Over the past three months, patient screening by participating hospitals and patient enrollment have steadily
Selinexor (KPT-330), is a first-in-class, oral selective inhibitors of nuclear export (SINE) compound that covalently inhibits exportin-1 (XPO1/CRM1), which leads to the accumulation of tumor suppressor proteins in
The sales and marketing of Khedezla will be supported by Pernix’s team of approximately 90 sales professionals, promoting the product to high desvenlafaxine prescribing physicians. The new drug
The contract was originally awarded in February 2011, with funding of up to $97m over an initial base period ending in February 2014. Novavax and BARDA have agreed
Aires’ lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the US and European Union for the treatment of pulmonary
A second NOA has been received for US Patent Application Serial No. 11/782,838 entitled ‘Controlled-release pharmaceutical tablets’ which is related to the drug delivery technology used in Forfivo
The call for proposals comes after newly released recommendations from the Society for Healthcare Epidemiology of America (SHEA) shed light on the issue of contaminated healthcare personnel apparel
The allowed claims for US Patent Application No. 12/528,690 entitled ‘Composition and Methods for Modulating Cell Proliferation and Cell Death’, cover a core element of Rosetta Genomics’ microRNA
The patent covers the company’s carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients with fatty liver disease with or without fibrosis or cirrhosis, providing patent protection through
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.